Ruqin Chen, M.D., M.B.

  1. Oncologist

Publications

  1. Shi H, Seegobin K, Heng F, Zhou K, Chen R, Qin H, Manochakian R, Zhao Y, Lou Y. Genomic landscape of lung adenocarcinomas in different races. Front Oncol. 2022; 12:946625 Epub 2022 Sept 28
    View PubMed
  2. Zhou K, Shi H, Chen R, Cochuyt JJ, Hodge DO, Manochakian R, Zhao Y, Ailawadhi S, Lou Y. Association of Race, Socioeconomic Factors, and Treatment Characteristics With Overall Survival in Patients With Limited-Stage Small Cell Lung Cancer. JAMA Netw Open. 2021 Jan 4; 4 (1):e2032276 Epub 2021 Jan 04
    View PubMed
  3. Chen R, Manochakian R, James L, Azzouqa AG, Shi H, Zhang Y, Zhao Y, Zhou K, Lou Y. Emerging therapeutic agents for advanced non-small cell lung cancer. J Hematol Oncol. 2020 May 24; 13 (1):58
    View PubMed
  4. Bischin AM, Vishnu P, Chen R, Knopf KB, Aboulafia DM. Quality Initiative in Clinical Practice: A Single-Institution Appraisal of Quality Metrics in the Management of Newly Diagnosed Diffuse Large B-Cell Lymphoma. Mayo Clin Proc Innov Qual Outcomes. 2019 Dec; 3 (4):485-494 Epub 2019 Oct 22
    View PubMed
  5. Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, Chen R, Dienstag J, Mrad C, Bergagnini I, Lai WV, Offin M, Arbour KC, Plodkowski AJ, Halpenny DF, Paik PK, Li BT, Riely GJ, Kris MG, Rudin CM, Sholl LM, Nishino M, Hellmann MD, Rekhtman N, Awad MM, Drilon A. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol. 2018 Oct 1; 29 (10):2085-2091
    View PubMed
  6. Sindhu H, Chen R, Chen H, Wong J, Chaudhry R, Xu Y, Wang JC. Gamma-delta (gammadelta) T-cell lymphoma - another case unclassifiable by World Health Organization classification: a case report. J Med Case Rep. 2017 Jun 19; 11 (1):163 Epub 2017 June 19
    View PubMed
  7. Sabari JK, Santini FC, Schram AM, Bergagnini I, Chen R, Mrad C, Lai WV, Arbour KC, Drilon A. The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers. Onco Targets Ther. 2017; 10:1983-1992 Epub 2017 Apr 06
    View PubMed
  8. Ansari RH, Socinski MA, Edelman MJ, Belani CP, Gonin R, Catalano RB, Marinucci DM, Comis RL, Obasaju CK, Chen R, Monberg MJ, Treat J, Alpha Oncology Research Network. A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer. Crit Rev Oncol Hematol. 2011 May; 78 (2):162-71 Epub 2010 Apr 21
    View PubMed
  9. Treat J, Edelman MJ, Belani CP, Socinski MA, Monberg MJ, Chen R, Obasaju CK, Alpha Oncology Research Network. A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. Lung Cancer. 2010 Dec; 70 (3):340-6 Epub 2010 Mar 27
    View PubMed
  10. Obasaju CK, Ansari RH, Socinski MA, Chen R, Monberg MJ, Catalano RB, Marinucci DM, Liles DK, Ribeiro MJ, Comis RL, Treat J, Alpha Oncology Research Network. A Comparison of white and African American outcomes from a three-arm, randomized, phase III multicenter trial of advanced or metastatic non-small cell lung cancer. J Thorac Oncol. 2010 Jul; 5 (7):993-1000
    View PubMed
  11. Edelman MJ, Belani CP, Socinski MA, Ansari RH, Obasaju CK, Chen R, Monberg MJ, Treat J, Alpha Oncology Research Network. Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. J Thorac Oncol. 2010 Jan; 5 (1):110-6
    View PubMed
  12. Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Waterhouse DM, Bromund JL, Chen R, Hristova-Kazmierski M, Treat J, Obasaju CK, Marciniak M, Gill J, Schiller JH. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Feb 1; 27 (4):591-8 Epub 2008 Dec 15
    View PubMed
  13. Socinski MA, Raju RN, Neubauer M, Smith DA, Richards DA, Savin M, Ruxer RL, Reynolds CH, Zhan F, Bromund JL, Chen R, Obasaju C. Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial. J Thorac Oncol. 2008 Nov; 3 (11):1308-16
    View PubMed
  14. Kulkarni PM, Chen R, Anand T, Monberg MJ, Obasaju CK. Efficacy and safety of pemetrexed in elderly cancer patients: results of an integrated analysis. Crit Rev Oncol Hematol. 2008 Jul; 67 (1):64-70 Epub 2008 Mar 20
    View PubMed
  15. Dudek AZ, Larson T, McCleod MJ, Schneider DJ, Dowell JE, Banerjee TK, Pandya KJ, Bromund JL, Chen R, Monberg MJ, Obasaju CK. Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer. J Thorac Oncol. 2008 Apr; 3(4):394-9.
    View PubMed
  16. Treat J, Bonomi P, McCleod M, Christiansen NP, Mintzer DM, Monberg MJ, Ye Z, Chen R, Obasaju CK. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial. Lung Cancer. 2006 Jul; 53 (1):77-83 Epub 2006 May 30
    View PubMed
  17. Levy H, Small D, Heiselman DE, Riker R, Steingrub J, Chen R, Qualy RL, Darstein C, Mongan E. Obesity does not alter the pharmacokinetics of drotrecogin alfa (activated) in severe sepsis. Ann Pharmacother. 2005 Feb; 39 (2):262-7 Epub 2005 Jan 04
    View PubMed
  18. Guan Z, Chen R, Xu G. Gemcitabine in the treatment of advanced non-small-cell lung cancer. Chinese Journal of Cancer. 1999; 18(3): 241.
PST-20523132